

Attorney Docket No.: **WARF-0015**
Inventors: **Anderson et al.**
Serial No.: **10/606,038**
Filing Date: **June 25, 2003**
Page 3

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A method for identifying an agent that modulates the activity of PIPKI γ 661 comprising contacting PIPKI γ 661 with a test agent in the presence of at least one selected protein, detecting the activity of PIPKI γ 661, wherein a change the activity of PIPKI γ 661 as compared to a control is indicative of said agent modulating the activity of PIPKI γ 661.

Claim 2 (original): The method of claim 1, wherein the selected protein is Src and the agent modulates the activity of Src.

Claim 3 (original): The method of claim 1, wherein the selected protein is Src and FAK and the agent modulates the activity of FAK.

Claim 4 (original): A method for identifying an agent that modulates cell focal adhesion assembly comprising contacting a cell which lacks active PIPKI γ 661 or which overexpresses PIPKI γ 661 with a test agent and measuring the adherence of said cell to a surface, wherein a difference in the adherence of the cell to the surface in the presence of the test agent as compared to the adherence of the cell to the surface in the absence of the

Attorney Docket No.: **WARF-0015**
Inventors: **Anderson et al.**
Serial No.: **10/606,038**
Filing Date: **June 25, 2003**
Page 4

test agent is indicative of the agent modulating cell focal adhesion assembly.

Claim 5 (original): A method of preventing or treating a cell migration-mediated condition or disease in a subject comprising administering to a subject an effective amount of an agent that modulates the activity of PIPKI γ 661 or cell focal adhesion assembly in a cell lacking active PIPKI γ 661 or which overexpresses PIPKI γ 661 so that at least one sign or symptom of a cell migration-mediated condition or disease is prevented or treated.